The Genetic Blueprint of Diabetes
Unlocking Pathways to Cure
- 1st Edition - June 1, 2027
- Latest edition
- Editors: Meenakshi Dhanawat, Dilip Sharma
- Language: English
The Genetic Blueprint of Diabetes: Unlocking Pathways to Cure is a comprehensive, advanced resource targeting biomedical researchers, clinicians, and graduate students focuse… Read more
Description
Description
Key features
Key features
- Integrates genetics, epigenetics, environment, immunology, and emerging therapies in resource focused specifically on diabetes
- Addresses ethical, policy, and equity issues related to genetic interventions
- Applies practical applications of cutting-edge technologies to patient care
Readership
Readership
Table of contents
Table of contents
2. Epigenetics and Diabetes: Beyond the DNA Code
3. Gene-Environment Interactions in Diabetes Susceptibility
4. Beta-Cell Biology and Genetic Regulation in Diabetes
5. Autoimmunity in Type 1 Diabetes: Genetic Triggers and Immune Pathways
6. Insulin Resistance: Genetic Underpinnings in Type 2 Diabetes
7. Mitochondrial Genetics and Metabolic Dysfunction in Diabetes
8. The Role of the Gut Microbiome and Metagenome in Diabetes
9. Pharmacogenomics in Diabetes: Toward Personalized Medicine
10. Gene Therapy and Genome Editing in Diabetes: Current Advances
11. Regenerative Medicine and Beta-Cell Replacement Therapy
12. Biomarkers and Predictive Genetics for Early Detection
13. From Blueprint to Cure: Ethical and Clinical Perspectives on Genetic Interventions
Product details
Product details
- Edition: 1
- Latest edition
- Published: June 1, 2027
- Language: English
About the editors
About the editors
Meenakshi Dhanawat
Meenakshi Dhanawat is Associate Professor at the Amity Institute of Pharmacy, Amity University Haryana, India. Her research spans medicinal chemistry, synthetic and heterocyclic chemistry, nanotechnology, drug delivery systems, prodrug design, complexation, polymer chemistry, and herbal drug extraction, with a particular focus on central nervous system drug delivery. She is a recipient of the Rajiv Gandhi National Fellowship.
Dilip Sharma
Dilip Sharma is a pharmacologist whose research spans neuroscience, molecular biology, and translational medicine. He is currently Assistant Professor in the Amity Institute of Pharmacy, India. Prior to this, he completed postdoctoral training in Anesthesiology at Rutgers New Jersey Medical School, where he developed rodent models of diabetic and chemotherapy-induced neuropathic pain. His earlier work investigated Rho-kinase-inhibitory GLP-1 secretagogues for diabetic nephropathy. He serves as a reviewer and editorial board member for several journals.